Managing transplant ineligible AML patients
SPIRIT2 trial on dasatinib for AML - safety and side effect management
Are newer, targeted agents better for the management of untreated CLL than chemoimmunotherapy?
The story behind targeting FLT3 in AML and the next generation of inhibitors
Is gilteritinib the new breakthrough in the treatment of FLT3-mutated AML?